Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.51 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.51 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.51 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | GRM6 | O15303 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | VCAM1 | P19320 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL159009 | 0.98 | MAPT (0.53) | MAPTGRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL30456072 | 0.97 | MAPT (0.51) | MAPTGRIA1GRIA2GRIA3GRIA4 | |
| Water SCHEMBL30261034 | 0.97 | MAPT (0.51) | MAPTGRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL6674172 | 0.83 | GRIA1 (0.34) | MAPTGRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL1998053 | 0.82 | CYP3A4 (0.43) | MAPTGRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL29597249 | 0.80 | MAPT (0.46) | MAPTGRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL157744 | 0.80 | CYP3A4 (0.45) | MAPTGRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL30389963 | 0.78 | CYP3A4 (0.43) | MAPTGRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL21292987 | 0.71 | VCAM1 (0.47) | MAPTGRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL7640581 | 0.69 | MAPT (0.58) | MAPTGRIA1GRIA2GRIA3GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110244486-A1 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF DIABETES | PEREGO, CARLA (IT) | 2011-10-06 | — | — | US | claimed |
| EP-2366106-A2 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF DIABETES | Perego, Carla (IT) | 2011-09-21 | — | — | EP | claimed |
| WO-2010057647-A2 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF DIABETES | UNIVERSITA' DEGLI STUDI DI MILANO (IT) | 2010-05-27 | — | — | WO | claimed |
| EP-1138332-B1 | Treatment of poriomania | AJINOMOTO KK (JP) | 2004-06-09 | — | — | EP | claimed |
| US-12616807-B2 | Medical counter measures including dry powder formulations and associated methods | Belhaven BioPharma Inc. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20240299680-A1 | MEDICAL COUNTER MEASURES INCLUDING DRY POWDER FORMULATIONS AND ASSOCIATED METHODS | Belhaven BioPharma Inc. (US) | 2024-09-12 | — | — | US | disclosed |
| US-12005185-B2 | Medical counter measures including dry powder formulations and associated methods | Belhaven BioPharma Inc. (US) | 2024-06-11 | — | — | US | disclosed |
| WO-2023114462-A1 | MEDICAL COUNTER MEASURES INCLUDING DRY POWDER FORMULATIONS AND ASSOCIATED METHODS | Belhaven BioPharma Inc. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20230191047-A1 | MEDICAL COUNTER MEASURES INCLUDING DRY POWDER FORMULATIONS AND ASSOCIATED METHODS | Belhaven BioPharma Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023028375-A1 | COMPOSITIONS AND SYSTEMS COMPRISING THREE-DIMENSIONAL NERVE CELL CULTURES AND METHODS OF USING THE SAME | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2023-03-02 | — | — | WO | disclosed |
| US-10183008-B2 | Treatment of prolonged status epilepticus | UNIVERSITY OF SOUTH CAROLINA (US) | 2019-01-22 | — | — | US | disclosed |
| EP-2710120-B1 | STABLE ELECTRICALLY ACTIVE NEURONS FROM ADULT TISSUE | UNIV CENTRAL FLORIDA RES FOUND INC (US) | 2017-03-29 | — | — | EP | disclosed |
| US-6939894-B2 | Methods for reducing excessive barking of a dog | AJINOMOTO CO., INC. (JP) | 2005-09-06 | — | — | US | disclosed |
| CN-1617676-A | Method of fattening poultry | AJINOMOTO KK (JP) | 2005-05-18 | — | — | CN | disclosed |
| US-20040219189-A1 | Methods of fattening fowls | AJINOMOTO CO., INC. (JP) | 2004-11-04 | — | — | US | disclosed |
| EP-1270002-B1 | Pharmaceutical compositions for preventing problem behaviour of companion animals | AJINOMOTO KK (JP) | 2004-09-15 | — | — | EP | disclosed |
| EP-1452096-A1 | METHOD OF FATTENING POULTRY | Ajinomoto Co., Inc. (JP) | 2004-09-01 | — | — | EP | disclosed |
| US-20030018027-A1 | Methods and pharmaceutical compositions for preventing problem behaviors of companion animals | AJINOMOTO CO., INC. (JP) | 2003-01-23 | — | — | US | disclosed |
| EP-1270002-A2 | Pharmaceutical compositions for preventing problem behaviour of companion animals | Ajinomoto Co., Inc. (JP) | 2003-01-02 | — | — | EP | disclosed |
| WO-1999056537-A2 | BIOLOGICAL PEST CONTROL METHODS AND COMPOSITIONS | THE HORTICULTURE AND FOOD RESEARCH INSTITUTE OF NEW ZEALAND LIMITED (NZ) | 1999-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183008-B2 | Treatment of prolonged status epilepticus | GABRE, GABRA2, GABRG3 | MAPT 230/4885GRIA1 541/4885GRIA2 289/4885 |
| US-12616807-B2 | Medical counter measures including dry powder formulations and associated methods | ADRB2, ADRB3, MC5R | MAPT 1011/4885GRIA1 1312/4885GRIA2 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.